pillsWhat makes clinical trials in orphan indications so special? Dr. Stephan de la Motte, SynteractHCR’s Chief Medical Advisor, addresses the unique characteristics of clinical trials for orphan indications in this PowerPoint primer on the topic.
Download the presentation.


SynteractHCR is a full-service CRO with more than two decades of success delivering customized Phase I-IV clinical trial solutions, contributing to numerous product approvals across multiple therapeutic areas. More...

Latest News


A SynteractHCR company, The European Centre for Clinical Research Training, is recognized as an official training facility by TransCelerate BioPharma Inc. More...

April 08, 2014

SynteractHCR will make a charity contribution by collecting donations, clothes and hygiene kits to support the San Diego Rescue Mission for second year in a row More...

November 12, 2013

SynteractHCR joins the fight for breast cancer in “Making Strides Against Breast Cancer” Fundraising Walk to support the American Cancer Society More...

October 17, 2013

What is the ICD+ platform?

SynteractHCR executives outline
how we take time and cost out
of drug development with our
Intelligent Clinical Development
(ICD+) platform.

Watch video